Year None202120202019201820172016 May 7, 2021 Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma Go to April 21, 2021 Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer Go to April 14, 2021 Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference Go to April 12, 2021 Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting Go to March 25, 2021 Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit Go to March 11, 2021 Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021 Go to Pagination Current page 1 Page 2 Next page next › Last page last »
May 7, 2021 Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma Go to
April 21, 2021 Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer Go to
April 12, 2021 Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting Go to
March 25, 2021 Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit Go to
March 11, 2021 Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021 Go to
